Last sale prices: Data provided for free by IEX. By accessing or using IEX Historical Data, you agree to the IEX Historical Data Terms of Use.
| Period | Ended | Value | Kind | Source trail |
|---|---|---|---|---|
| FY 2025 | 2025-12-31 | $7,498,000 | reported | |
| FY 2024 | 2024-12-31 | $9,587,000 | reported | |
| FY 2023 | 2023-12-31 | $7,143,000 revised | reported | |
| FY 2022 | 2022-12-31 | $14,572,000 revised | reported | |
| FY 2021 | 2021-12-31 | $5,260,000 | reported | |
| FY 2020 | 2020-12-31 | $3,652,000 | reported | |
| FY 2019 | 2019-12-31 | $532,000 | reported | |
| FY 2018 | 2018-12-31 | $26,881,000 | reported | |
| FY 2017 | 2017-12-31 | $923,000 | reported | |
| FY 2016 | 2016-12-31 | $911,000 | reported | |
| FY 2015 | 2015-12-31 | $545,000 | reported |
COSCIENS Biopharma Inc. · CIK 1113423 · Engraved from SEC EDGAR
COSCIENS Biopharma Inc. is the 15th largest of the 19 covered companies the SEC files under this code, by revenue. SIC 2844
Latest filing Jul 6, 2026
The ifrs-full concepts with the most facts on file for this company.
Peers are the covered companies filed under the same SIC code, then under codes that share its first three digits or its first two, nearest in revenue first. Figures are each company’s latest fiscal year as filed; market cap is at its latest price.
No reported open-market purchases or sales in the last 12 months.
2 managers · Quarter ended Sep 30, 2025All holders ›
0